Similarly, p-Tau181 [65,[75], [76], [77], [78]] and p-S396-Tau [79] were significantly elevated in the CSF and plasma of patients with AD, and p-Tau181 in plasma reached a peak 4–8 years before patient death and stabilized thereafter, indicating its potential prognostic predictive value [80]. Here, MAPT is linked to Alzheimer disease.